Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Characterization of Myeloproliferative Neoplasia With a Mutated IDH, SRSF2 or SF3B1 Allele

NCT06481345 is registered in ClinicalTrials.gov with University Hospital, Brest as lead sponsor.

NCT NCT06481345
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06481345 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Characterization of Myeloproliferative Neoplasia With a Mutated IDH, SRSF2 or SF3B1 Allele
Lead sponsor
University Hospital, Brest
Phase
Observational
Overall status
Unknown status
Start date
June 25, 2024
Completion date
May 31, 2026
Enrollment
300 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

myeloproliferative disorders